Skip to content

Stephen Bright

Edith Cowan University

8 papers in the library · 94 citations · publishing 2017-2026

Papers

Current Perspective on the Therapeutic Preset for Substance-Assisted Psychotherapy

Frontiers in Psychology July 13, 2021 Sascha Thal, Stephen Bright, Jason M. Sharbanee et al. 39 citations

This narrative review, the first in a series on appropriate conduct in substance-assisted psychotherapy (SAPT), outlines preconditions and theoretical knowledge valuable for therapeutic practice. It discusses ethical considerations and the spiritual emphasis of SAPT approaches, and summarizes current methods, models, and concepts of psychological mechanisms and therapeutic effects. Similarities between models and potential mediators for therapeutic effects are highlighted. The review argues that the therapeutic effect of SAPT may be mediated by intra- and interpersonal variables within the therapeutic context rather than specific therapeutic models per se. It provides a basis for developing future investigations, therapeutic models, and training programs, while discussing limitations and future directions.

Tripping over the other: Could psychedelics increase empathy?

Journal of Evolutionary Psychology September 21, 2020 Emily Blatchford, Stephen Bright, Liam Engel 27 citations

Psychedelic-assisted psychotherapy shows promise for treating various psychological conditions, and increased empathic functioning may be one mechanism behind its clinical effects. Neuropsychological and clinical evidence suggests that psychedelics can enhance empathy through actions on the 5-HT system, default mode network, neural connectivity, and ego dissolution. These changes in empathy are likely linked to well-documented increases in the personality trait of openness following psychedelic use. Enhanced empathic function may have clinical benefits by fostering greater social connectedness and promoting prosocial attitudes and behaviors.

Exploring the relationship between microdosing, personality and emotional insight: A prospective study

Journal of Psychedelic Studies March 26, 2021 Hannah Marie Dressler, Stephen Bright, Vince Polito 12 citations

Microdosing—taking very small, sub-perceptual doses of psychedelic drugs—is associated with increases in conscientiousness and decreases in neuroticism over a 31-day period. Among 24 participants who completed both surveys, neuroticism was linked to alexithymia (difficulty identifying emotions) at baseline, and longer prior microdosing experience correlated with lower neuroticism and higher extraversion. The findings suggest that microdosing may alter typically stable personality traits.

Dosing and Therapeutic Conduct in Administration Sessions in Substance-Assisted Psychotherapy: A Systematized Review

Journal of Humanistic Psychology May 3, 2023 Sascha Thal, Michelle Wieberneit, Jason M. Sharbanee et al. 6 citations

A systematized review of 82 sources examined best therapeutic practices during administration sessions with serotonergic psychedelics and entactogens as adjuncts to psychotherapy. Information about substances, dosages, number of sessions, common client issues, types of experiences, music, and therapeutic conduct was summarized and compared. The effects of different therapeutic models, methods, techniques, and complex interventions on outcomes have not been rigorously investigated. Most available evidence was anecdotal, limiting conclusive statements about appropriate therapeutic conduct. Essential components of therapeutic interventions remain largely tentative, necessitating systematic investigation.

Should addiction researchers be interested in psychedelic science?

Drug and Alcohol Review April 10, 2017 Stephen Bright, M.l. Williams, David Caldicott 5 citations

Psychedelic-assisted psychotherapies, using psilocybin, LSD, or MDMA, show promise for treating depression, anxiety, PTSD, and substance use disorders, with recent randomized controlled trials reporting significant improvements. For example, psilocybin-assisted therapy helped 80% of participants quit smoking at 6 months, and MDMA-assisted therapy led to 86% of participants no longer meeting PTSD criteria. Despite a renaissance in research elsewhere, Australia has conducted no such studies, facing barriers like institutional vetoes. The authors argue addiction researchers should follow these developments, as psychedelics may enhance psychotherapy for trauma-related substance use disorders, potentially paradigm-changing.

Psychedelic trip sitting, dosages and intensities: Supplementing clinical studies with anecdotal reports

Journal of Psychedelic Studies July 17, 2024 Liam Engel, Sascha Thal, Stephen Bright et al. 4 citations

Analysis of 660 posts from online psychedelic forums (The Shroomery and DMT Nexus) about trip sitting revealed that psychedelics discussed include 5-MeO-DMT, ayahuasca, changa, LSA, LSD, and psilocybin. For well-researched substances like LSD and psilocybin, the common dosages determined by a Delphi-style expert panel aligned closely with those used in clinical studies. Many posts indicated that psychedelic care was seen as unnecessary or optional, especially for LSD and LSA, while 5-MeO-DMT was strongly associated with a perceived need for care. Greater psychedelic purity and dosage intensity correlated with a perceived need for care. Oral administration, the most common route, showed lower dosage intensity.

Therapeutic frameworks in integration sessions in substance‐assisted psychotherapy: A systematised review

Clinical Psychology & Psychotherapy December 26, 2023 Sascha Thal, Paris Baker, Jonathon Marinis et al. 1 citation

Serotonergic psychedelics and entactogens are being studied as adjuncts in substance-assisted psychotherapy (SAPT) for various disorders. SAPT includes three phases: preparation, administration, and integration, where insights from the psychedelic experience are applied to everyday life. A systematised review of 75 publications found that the effects of different therapeutic approaches for integration sessions on outcomes have not been rigorously investigated. Most available evidence lacks empirical data, limiting conclusions about appropriate frameworks. Current clinical studies mostly draw from the humanistic–experiential tradition. Although integration is considered crucial for safe SAPT, there is insufficient evidence to suggest any therapy type is effective for guiding integration sessions.

“You can only take your clients as far as you’ve been yourself”: examining the intersections between psychedelic-assisted therapy, lived-living experience, and clinical practice

Drugs Education Prevention and Policy March 22, 2026 Jordan J. Negrine, Stephen Bright, Monica J. Barratt et al.

In interviews, twenty Australian psychologists expressed that a therapist's own lived or living experience with psychedelics could enhance empathy, confidence, and therapeutic rapport in psychedelic-assisted therapy, especially given lingering stigma. They noted that the intense, altered states of PAT demand deeper therapist familiarity, which lived experience may uniquely improve beyond standard training. Most supported optional, safe, and structured inclusion of such experience in formal training, respecting ethical considerations. The findings indicate growing professional openness to experiential learning as a valuable, though not mandatory, component of preparing psychedelic therapists.